Robert W. Baird reaffirmed their hold rating on shares of Tesaro (NASDAQ:TSRO) in a research note published on Tuesday.
Several other analysts have also issued reports on the company. Lake Street Capital set a $120.00 price objective on Tesaro and gave the stock a buy rating in a report on Sunday. BidaskClub lowered Tesaro from a sell rating to a strong sell rating in a report on Friday, April 20th. HC Wainwright reiterated a buy rating and set a $108.00 price objective on shares of Tesaro in a report on Tuesday, March 27th. ValuEngine upgraded Tesaro from a sell rating to a hold rating in a report on Friday, March 2nd. Finally, Morgan Stanley cut their price objective on Tesaro from $156.00 to $146.00 and set an overweight rating for the company in a report on Thursday, March 1st. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and fourteen have issued a buy rating to the company. Tesaro currently has an average rating of Hold and a consensus target price of $128.26.
Shares of NASDAQ:TSRO opened at $53.02 on Tuesday. The company has a quick ratio of 4.39, a current ratio of 4.74 and a debt-to-equity ratio of 1.75. Tesaro has a 1 year low of $50.67 and a 1 year high of $168.92. The firm has a market cap of $2,826.67, a P/E ratio of -5.78 and a beta of 1.34.
Tesaro (NASDAQ:TSRO) last announced its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($3.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.39) by ($0.96). Tesaro had a negative return on equity of 126.44% and a negative net margin of 222.15%. The firm had revenue of $48.02 million for the quarter, compared to analysts’ expectations of $51.78 million. analysts anticipate that Tesaro will post -9.44 earnings per share for the current year.
In other news, VP Grant C. Bogle sold 1,809 shares of the firm’s stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $54.85, for a total value of $99,223.65. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Orlando Oliveira sold 3,000 shares of the firm’s stock in a transaction dated Thursday, March 8th. The shares were sold at an average price of $69.88, for a total value of $209,640.00. Following the completion of the sale, the senior vice president now directly owns 9,076 shares in the company, valued at $634,230.88. The disclosure for this sale can be found here. Over the last three months, insiders have acquired 334,913 shares of company stock worth $19,083,294 and have sold 13,042 shares worth $760,526. Corporate insiders own 33.70% of the company’s stock.
Several large investors have recently modified their holdings of the company. BlackRock Inc. grew its position in shares of Tesaro by 5.6% in the fourth quarter. BlackRock Inc. now owns 4,067,066 shares of the biopharmaceutical company’s stock valued at $337,039,000 after purchasing an additional 213,920 shares during the last quarter. TimesSquare Capital Management LLC grew its position in shares of Tesaro by 226.1% in the fourth quarter. TimesSquare Capital Management LLC now owns 856,600 shares of the biopharmaceutical company’s stock valued at $70,986,000 after purchasing an additional 593,924 shares during the last quarter. Rock Springs Capital Management LP grew its position in shares of Tesaro by 10.8% in the fourth quarter. Rock Springs Capital Management LP now owns 548,500 shares of the biopharmaceutical company’s stock valued at $45,454,000 after purchasing an additional 53,250 shares during the last quarter. Alliancebernstein L.P. grew its position in shares of Tesaro by 16.9% in the fourth quarter. Alliancebernstein L.P. now owns 513,542 shares of the biopharmaceutical company’s stock valued at $42,557,000 after purchasing an additional 74,290 shares during the last quarter. Finally, Renaissance Technologies LLC grew its position in shares of Tesaro by 482.1% in the fourth quarter. Renaissance Technologies LLC now owns 357,400 shares of the biopharmaceutical company’s stock valued at $29,618,000 after purchasing an additional 296,000 shares during the last quarter.
TRADEMARK VIOLATION WARNING: This report was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/25/tesaro-tsro-given-hold-rating-at-robert-w-baird.html.
Tesaro Company Profile
Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.
Receive News & Ratings for Tesaro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro and related companies with MarketBeat.com's FREE daily email newsletter.